Thymosin alpha-1 treatment in chronic hepatitis B

Bibliography

• Schulof RS, Low TL, Thurman GB, et al. Thymosins and other hormones of the thymus gland. Prog Clin Biol Res 1981;58:191-215
   PubMedGoogle Scholar
• Low TL, Goldstein AL. Thymosins: structure, function and therapeutic applications. Thymus 1984;6:27-42
   PubMedGoogle Scholar
• Goldstein AL, Goldstein AL. From lab to bedside: emerging clinical applications of thymosin alpha 1. Expert Opin Biol Ther 2009;9:593-608
   PubMed Web of Science ®Google Scholar
• Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60
   PubMed Web of Science ®Google Scholar
• Sherman KE, Jones CC, Goldstein AL, et al. Low thymosin alpha-1 concentrations in patients chronically infected with the hepatitis B virus. Viral Immunol 1991;4:195-9
   PubMedGoogle Scholar
• Sugahara S, Ichida T, Yamagiwa S, et al. Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B. Hepatol Res 2002;24:346-54
   PubMed Web of Science ®Google Scholar
• Li CL, Zhang T, Saibara T, et al. Thymosin alpha1 accelerates restoration of T cell-mediated neutralizing antibody response in immunocompromised hosts. Int Immunopharmacol 2002;2:39-46
   PubMed Web of Science ®Google Scholar
• Mutchnick MG, Appelman HD, Chung HT, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology 1991;14:409-15
   PubMed Web of Science ®Google Scholar
• Chien RN, Liaw YF, Chen TC, et al. Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial. Hepatology 1998;27:1383-7
   PubMed Web of Science ®Google Scholar
• Mutchnick MG, Jaurequi JI, Shafritz DA. Sustained response to thymosin therapy in patients with chronic hepatitis B. Hepatology 1992;16:66A
   PubMed Web of Science ®Google Scholar
• Mutchnick MG, Lindsay KL, Schiff ER, et al. Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. J Viral Hepat 1999;6:397-403
   PubMed Web of Science ®Google Scholar
• Zavaglia C, Severini R, Tinelli C, et al. A randomized, controlled study of thymosin-alpha1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B. Dig Dis Sci 2000;45:690-6
   PubMed Web of Science ®Google Scholar
• Chan HL, Tang JL, Tam W, et al. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment Pharmacol Ther 2001;15:1899-905
   PubMed Web of Science ®Google Scholar
• Chien RN, Lin CY, Yeh CT, et al. Hepatitis B virus genotype B is associated with better response to thymosin alpha1 therapy than genotype C. J Viral Hepat 2006;13:845-50
   PubMed Web of Science ®Google Scholar
• Andreone P, Cursaro C, Gramenzi A, et al. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody-and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 1996;24:774-7
   PubMed Web of Science ®Google Scholar
• You J, Zhuang L, Tang BZ, et al. A randomized controlled clinical trial on the treatment of thymosin–alpha 1 versus interferon-alpha in patients with hepatitis B. World J Gastroenterol 2001;7:411-14
   PubMed Web of Science ®Google Scholar
• You J, Zhuang L, Cheng HY, et al. A randomized, controlled, clinical study of thymosin alpha-1 versus interferon-alpha in patients with chronic hepatitis B lacking HBeAg in China. J Chin Med Assoc 2005;68:65-72
   PubMedGoogle Scholar
• Zhuang L, You J, Tang BZ, et al. Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. World J Gastroenterol 2001;7:407-10
   PubMed Web of Science ®Google Scholar
• Yang YF, Zhao W, Zhong YD, et al. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res 2008;77:136-41
   PubMed Web of Science ®Google Scholar
• Zhang YY, Chen EQ, Yang J, et al. Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis. Virol J 2009;6:63
   PubMedGoogle Scholar
• Lau GK, Nanji A, Hou J, et al. Thymosin alpha-1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase. J Viral Hepat 2002;9:280-7
   PubMed Web of Science ®Google Scholar
• Saruc M, Ozden N, Turkel N, et al. Long-term outcomes of thymosin-alpha 1 and interferon alpha-2b combination therapy in patients with hepatitis B e antigen negative chronic hepatitis B. J Pharm Sci 2003;92:1386-95
   PubMed Web of Science ®Google Scholar
• Saruc M, Yuceyar H, Kucukmetin N, et al. Combination thymosin-alpha 1 and interferon-alpha 2b in the treatment of anti-HBe-positive chronic hepatitis B in Turkey. Hepatogastroenterology 2002;49:798-802
   PubMed Web of Science ®Google Scholar
• Mao HY, Shi TD. Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis. Zhonghua Gan Zang Bing Za Zhi 2011;19:29-33
   PubMedGoogle Scholar
• Kim BH, Lee YJ, Kim W, et al. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study. Scand J Gastroenterol 2012;47:1048-55
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gao JH, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012;6:531-61
   PubMed Web of Science ®Google Scholar